REFERENCES
1. White MT, Sears CL. The microbial landscape of colorectal cancer. Nat Rev Microbiol 2023; doi: 10.1038/s41579-023-00973-4.
2. Rassy E, Parent P, Lefort F, Boussios S, Baciarello G, Pavlidis N. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit? Crit Rev Oncol Hematol 2020;147:102882.
3. Ohishi T, Kaneko MK, Yoshida Y, Takashima A, Kato Y, Kawada M. Current targeted therapy for metastatic colorectal cancer. Int J Mol Sci 2023;24:1702.
4. Osseis M, Nehmeh WA, Rassy N, et al. Surgery for T4 colorectal cancer in older patients: determinants of outcomes. J Pers Med 2022;12:1534.
5. Leowattana W, Leowattana P, Leowattana T. Systemic treatment for metastatic colorectal cancer. World J Gastroenterol 2023;29:1569-88.
6. Augusti PR, Quatrin A, Mello R, et al. Antiproliferative effect of colonic fermented phenolic compounds from jaboticaba (myrciaria trunciflora) fruit peel in a 3D cell model of colorectal cancer. Molecules 2021;26:4469.
7. Adeleke S, Haslam A, Choy A, et al. Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls. Per Med 2022;19:277-86.
8. Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 2019;16:361-75.
9. Chen M, Lin W, Li N, et al. Therapeutic approaches to colorectal cancer via strategies based on modulation of gut microbiota. Front Microbiol 2022;13:945533.
10. Cheng Y, Ling Z, Li L. The intestinal microbiota and colorectal cancer. Front Immunol 2020;11:615056.
11. Alon-Maimon T, Mandelboim O, Bachrach G. Fusobacterium nucleatum and cancer. Periodontol 2000 2022;89:166-80.
12. Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol 2019;17:156-66.
13. Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14:207-15.
14. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14:195-206.
15. Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21. Gastroenterology 2017;152:851-866.e24.
16. Park BS, Lee JO. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med 2013;45:e66.
17. Zhou X, Jiao L, Qian Y, et al. Repositioning azelnidipine as a dual inhibitor targeting CD47/SIRPα and TIGIT/PVR pathways for cancer immuno-therapy. Biomolecules 2021;11:706.
18. Thuru X, Magnez R, El-Bouazzati H, Vergoten G, Quesnel B, Bailly C. Drug repurposing to enhance antitumor response to PD-1/PD-L1 immune checkpoint inhibitors. Cancers (Basel) 2022;14:3368.
19. Jia F, Yu Q, Zhao L, Shen Y, Guo H, He F. Sodium new houttuyfonate inhibits cancer-promoting fusobacterium nucleatum (Fn) to reduce colorectal cancer progression. Cancers (Basel) 2022;14:6111.
20. Jia F, Yu Q, Wang R, et al. Optimized antimicrobial peptide jelleine-I derivative Br-J-I inhibits fusobacterium nucleatum to suppress colorectal cancer progression. Int J Mol Sci 2023;24:1469.
21. Zheng DW, Dong X, Pan P, et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat Biomed Eng 2019;3:717-28.
22. Sun F, Zhang Q, Zhao J, Zhang H, Zhai Q, Chen W. A potential species of next-generation probiotics? Food Res Int 2019;126:108590.
23. Wu S, Rhee KJ, Zhang M, Franco A, Sears CL. Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretase-dependent E-cadherin cleavage. J Cell Sci 2007;120:1944-52.
25. Wang L, Yi T, Zhang W, Pardoll DM, Yu H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 2010;70:10112-20.
26. Brockmann L, Giannou AD, Gagliani N, Huber S. Regulation of T(H)17 cells and associated cytokines in wound healing, tissue regeneration, and carcinogenesis. Int J Mol Sci 2017;18:1033.
27. Shaked H, Hofseth LJ, Chumanevich A, et al. Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci U S A 2012;109:14007-12.
28. Kwon MJ, Hong E, Choi Y, Kang DH, Oh ES. Interleukin-1α promotes extracellular shedding of syndecan-2 via induction of matrix metalloproteinase-7 expression. Biochem Biophys Res Commun 2014;446:487-92.
29. Kim HR, Rhee KJ, Eom YB. Anti-biofilm and antimicrobial effects of zerumbone against Bacteroides fragilis. Anaerobe 2019;57:99-106.
30. Li S, Konstantinov SR, Smits R, Peppelenbosch MP. Bacterial biofilms in colorectal cancer initiation and progression. Trends Mol Med 2017;23:18-30.
31. Jang HI, Rhee KJ, Eom YB. Antibacterial and antibiofilm effects of α-humulene against Bacteroides fragilis. Can J Microbiol 2020;66:389-99.
32. Al-Hazmi NE, Naguib DM. Control the carcinogenic bacteria with new polysaccharides from agricultural wastes. Microb Pathog 2023;184:106343.
33. Jang HI, Eom YB. Antibiofilm and antibacterial activities of repurposing auranofin against Bacteroides fragilis. Arch Microbiol 2020;202:473-82.
34. Abdelhamid AG, Esaam A, Hazaa MM. Cell free preparations of probiotics exerted antibacterial and antibiofilm activities against multidrug resistant E. coli. Saudi Pharm J 2018;26:603-7.
35. Lv Y, Ye T, Wang HP, et al. Suppression of colorectal tumorigenesis by recombinant Bacteroides fragilis enterotoxin-2 in vivo. World J Gastroenterol 2017;23:603-13.
36. Liu M, Xie W, Wan X, Deng T. Clostridium butyricum modulates gut microbiota and reduces colitis associated colon cancer in mice. Int Immunopharmacol 2020;88:106862.
37. Zhou M, Yuan W, Yang B, Pei W, Ma J, Feng Q. Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF-κB) signaling pathway. Ann Transl Med 2022;10:478.
38. Chen D, Jin D, Huang S, et al. Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota. Cancer Lett 2020;469:456-67.
39. Xu H, Luo H, Zhang J, Li K, Lee MH. Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer. Gut Microbes 2023;15:2186114.
40. Xin M, Xie Q, Ma L, et al. Synergistic anti-tumour effects of Clostridium butyricum in combination with apatinib in CT26 colorectal tumour-bearing mice. Anticancer Drugs 2019;30:991-7.
41. Xiao Y, Dai X, Li K, Gui G, Liu J, Yang H. Clostridium butyricum partially regulates the development of colitis-associated cancer through miR-200c. Cell Mol Biol (Noisy-le-grand) 2017;63:59-66.
42. Zheng DW, Li RQ, An JX, et al. Prebiotics-encapsulated probiotic spores regulate gut microbiota and suppress colon cancer. Adv Mater 2020;32:e2004529.
43. Boleij A, Tjalsma H. The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease. Lancet Infect Dis 2013;13:719-24.
44. Kumar R, Herold JL, Schady D, et al. Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS Pathog 2017;13:e1006440.
45. Taddese R, Roelofs R, Draper D, et al. Streptococcus gallolyticus increases expression and activity of aryl hydrocarbon receptor-dependent CYP1 biotransformation capacity in colorectal epithelial cells. Front Cell Infect Microbiol 2021;11:740704.
46. Tsoi H, Chu ESH, Zhang X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology 2017;152:1419-1433.e5.
47. Long X, Wong CC, Tong L, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat Microbiol 2019;4:2319-30.
48. Hsu RY, Chan CH, Spicer JD, et al. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res 2011;71:1989-98.
49. Song W, Tiruthani K, Wang Y, et al. Trapping of lipopolysaccharide to promote immunotherapy against colorectal cancer and attenuate liver metastasis. Adv Mater 2018;30:e1805007.
50. Zhuang P, Zhang Y, Shou Q, et al. Eicosapentaenoic and Docosahexaenoic Acids differentially alter gut microbiome and reverse high-fat diet-induced insulin resistance. Mol Nutr Food Res 2020;64:e1900946.
51. Sorbara MT, Littmann ER, Fontana E, et al. Functional and genomic variation between human-derived isolates of lachnospiraceae reveals inter- and intra-species diversity. Cell Host Microbe 2020;28:134-146.e4.
52. Zhang X, Yu D, Wu D, et al. Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance. Cell Host Microbe 2023;31:418-432.e8.
53. Sugimura N, Li Q, Chu ESH, et al. Lactobacillus gallinarum modulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis. Gut 2021;71:2011-21.
54. Hill ID, Dirks MH, Liptak GS, et al. North American Society for Pediatric Gastroenterology; Hepatology and Nutrition. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005;40:1-19.
55. Marzio L, Cinque B, De Simone C, Cifone MG. Effect of the lactic acid bacterium Streptococcus thermophilus on ceramide levels in human keratinocytes in vitro and stratum corneum in vivo. J Invest Dermatol 1999;113:98-106.
56. Li Q, Hu W, Liu WX, et al. Streptococcus thermophilus Inhibits colorectal tumorigenesis through secreting β-galactosidase. Gastroenterology 2021;160:1179-1193.e14.
57. Zhang SL, Han B, Mao YQ, et al. Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice. Gut Microbes 2022;14:2046246.
58. Sun E, Zhang X, Zhao Y, et al. Beverages containing Lactobacillus paracasei LC-37 improved functional dyspepsia through regulation of the intestinal microbiota and their metabolites. J Dairy Sci 2021;104:6389-98.
59. Lv XC, Chen M, Huang ZR, et al. Potential mechanisms underlying the ameliorative effect of Lactobacillus paracasei FZU103 on the lipid metabolism in hyperlipidemic mice fed a high-fat diet. Food Res Int 2021;139:109956.
60. Chang CY, Pan TM. Anticancer and antimigration effects of a combinatorial treatment of 5-fluorouracil and lactobacillus paracasei subsp. paracasei NTU 101 fermented skim milk extracts on colorectal cancer cells. J Agric Food Chem 2018;66:5549-55.
61. Shi Y, Meng L, Zhang C, Zhang F, Fang Y. Extracellular vesicles of Lacticaseibacillus paracasei PC-H1 induce colorectal cancer cells apoptosis via PDK1/AKT/Bcl-2 signaling pathway. Microbiol Res 2021;255:126921.
62. Montalban-Arques A, Katkeviciute E, Busenhart P, et al. Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host Microbe 2021;29:1573-1588.e7.
63. Gur C, Maalouf N, Shhadeh A, et al. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1. Oncoimmunology 2019;8:e1581531.
64. Inamura K, Hamada T, Bullman S, Ugai T, Yachida S, Ogino S. Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science. Gut ;2022:2107-22.
65. Ogino S, Nowak JA, Hamada T, Milner DA Jr, Nishihara R. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu Rev Pathol 2019;14:83-103.
66. Yang J, Wei H, Zhou Y, et al. High-fat diet promotes colorectal tumorigenesis through modulating gut microbiota and metabolites. Gastroenterology 2022;162:135-149.e2.
67. Fu T, Coulter S, Yoshihara E, et al. FXR regulates intestinal cancer stem cell proliferation. Cell 2019;176:1098-1112.e18.
68. Sedlak JC, Yilmaz ÖH, Roper J. Metabolism and colorectal cancer. Annu Rev Pathol 2023;18:467-92.
69. Schwartz DJ, Langdon AE, Dantas G. Understanding the impact of antibiotic perturbation on the human microbiome. Genome Med 2020;12:82.
70. Becattini S, Taur Y, Pamer EG. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol Med 2016;22:458-78.
71. Kvakova M, Kamlarova A, Stofilova J, Benetinova V, Bertkova I. Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy. World J Gastroenterol 2022;28:3370-82.
72. Tripathy A, Dash J, Kancharla S, et al. Probiotics: a promising candidate for management of colorectal cancer. Cancers (Basel) 2021;13:3178.
73. Park IJ, Lee JH, Kye BH, et al. Effects of probiotics on the symptoms and surgical outcomes after anterior resection of colon cancer (POSTCARE): a randomized, double-blind, placebo-controlled trial. J Clin Med 2020;9:2181.
